A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Study Summary

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.

Conditions

Overweight or Obesity and Elevated Liver Fat

Interventions / Drugs

Maridebart cafraglutide Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment180 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157277+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.